Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

Characteristic Placebo, n = 410 (%) GV-971, n = 408 (%) p value
Age—years 69.7 ± 8.20 69.6 ± 8.12 0.7374 [b]
 ≤ 65 years 131 (32.0%) 132 (32.4%) 0.9021 [c]
 > 65 years 279 (68.0%) 276 (67.6%)  
Sex    0.8242 [c]
 Male—no. (%) 177 (43.2%) 173 (42.4%)  
 Female—no. (%) 233 (56.8%) 235 (57.6%)  
Han ethnicity—no. (%) 402 (98.0%) 398 (97.5%) 0.6261 [c]
Education—years    0.7394 [c]
 > 6 years 335 (81.7%) 337 (82.6%)  
 ≤ 6 years 75 (18.3%) 71 (17.4%)  
APOE ε4 carrier—no. (%) 199 (48.5%) 214 (52.5%) 0.2758 [c]
MMSE score 19.5 ± 4.5 19.4 ± 4.4 0.5795 [b]
 MMSE < 11 1 (0.2%) 0 0.6815 [d]
 11 ≤ MMSE < 15 72 (17.6%) 68 (16.7%)  
 15 ≤ MMSE ≤ 19 118 (28.8%) 122 (29.9%)  
 20 ≤ MMSE ≤ 26 219 (53.4%) 216 (52.9%)  
 26 < MMSE 0 2 (0.5%)  
Duration since symptom onset (months) 31.46 ± 20.79 30.42 ± 20.59 0.6087 [b]
ADAS-Cog12 20.88 ± 10.00 21.28 ± 10.14 0.5638 [b]
ADCS-ADL 64.2 ± 10.1 64.0 ± 11.2 0.8910 [b]
NPI 5.9 ± 8.6 5.6 ± 8.0 0.5651 [b]
  1. [a] refers to the t test; [b] refers to the Wilcoxon rank sum test; [c] refers to the chi-square test; [d] refers to Fisher’s exact test